 | Up a level |
Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253
Schwappach, D L B; Wernli, M (2011). Barriers and facilitators to chemotherapy patients' engagement in medical error prevention. Annals of oncology, 22(2), pp. 424-430. Oxford: Oxford University Press 10.1093/annonc/mdq346
Roth, AD; Fazio, N; Stupp, R; Falk, S; Bernhard, J; Saletti, P; Köberle, D; Borner, MM; Rufibach, K; Maibach, R; Wernli, M; Leslie, M; Glynne-Jones, R; Widmer, L; Seymour, M; de Braud, F; Swiss, Group for Clinical Cancer Research (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 25(22), pp. 3217-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.08.0135
Leyvraz, S; Herrmann, R; Guillou, L; Honegger, HP; Christinat, A; Fey, MF; Sessa, C; Wernli, M; Cerny, T; Dietrich, D; Pestalozzi, B; Swiss, Group for Clinical Cancer Research (SAKK) (2006). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer, 95(10), pp. 1342-7. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603420
Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB; ... (2006). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer, 94(8), pp. 1099-106. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603075
